LQV Branded Vial
Tirzepatide
Includes syringes and alcohol pads with every vial shipment.
Tirzepatide
Tirzepatide is a dual GIP/GLP-1 receptor agonist that targets two incretin pathways simultaneously. It has demonstrated significant efficacy in clinical weight loss trials and offers enhanced metabolic benefits compared to single-receptor therapies.
How It Works
Tirzepatide activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors, amplifying appetite suppression and improving insulin sensitivity through dual hormonal signaling. This combined mechanism leads to greater reductions in body weight and improved glycemic control.
Key Benefits
Who It Is For
Adults seeking a more aggressive weight loss approach who meet clinical criteria for pharmacological weight management. Particularly suited for individuals who have not achieved desired results with single-receptor GLP-1 therapies. Medical evaluation is required.
Common Side Effects
Common side effects include nausea, diarrhea, decreased appetite, vomiting, and injection site reactions. Side effects are generally dose-dependent and improve with continued use. Serious risks such as pancreatitis and gallbladder complications are rare but possible. Full risk profile is discussed during consultation.
Other GLP-1 Therapies
GLP-1 Therapy
Semaglutide
(SMA)
Semaglutide is a GLP-1 receptor agonist originally developed for type 2 diabetes management and now widely used for weight management. It helps reduce appetite, slow gastric emptying, and promote sustainable weight loss when combined with lifestyle modifications.
From $299
GLP-1 Therapy
Retatrutide
(RTA)
Retatrutide is a triple agonist targeting GLP-1, GIP, and glucagon receptors. By engaging three metabolic pathways, it represents the next generation of weight management therapies with the potential for greater efficacy in both weight loss and metabolic improvement.
From $449
GLP-1 Therapy
Cagrilintide
Cagrilintide is a long-acting amylin analog that enhances satiety signaling. It works through a distinct mechanism from GLP-1 therapies, targeting the amylin pathway to help patients feel full sooner and reduce overall food intake.
From $349
Frequently Asked Questions
A therapy that mimics natural gut hormones involved in appetite and blood sugar regulation.
Yes. Medical evaluation and monitoring are required for all GLP-1 therapies.
Yes, following medical review and protocol setup.
Yes. Use the Speak To Our Medical Team tab to submit a form and request a consultation.
Prescription therapies require medical evaluation and supervision. Results vary. Side effects and risks are discussed during consultation.